Abstract
At present, there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring show dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarkers does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “polluted” knowledge may have dramatic consequences for patient. A critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time can facilitate the research of new and more sensitive-specific signals of the cancer cell proliferation
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Watson J (2013) Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3:120144. doi:10.1098/rsob.120144
Gion M, Fabricio AS (2011) New frontiers in tumor marker studies: from biobanking to collaboration in translational research. Int J Biol Markers 26:73–74
Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577
Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS (2003) Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 100:14666–14671
Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini A, Pfeffer U (2014) Validation of proposed prostate cancer biomarkers with gene expression data: along road to travel. Cancer Metastasis Rev 33:657–671
Sturgeon CM, Hoffman BR, Chan DW, Ch’ng SL, Hammond E, Hayes DF, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Söletormos G, van der Merwe E, Diamandis EP (2008) National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 54:e1–e10
Ellis MJ, Gillette M, Carr SA, Paulovich AG, Smith RD, Rodland KK, Townsend RR, Kinsinger C, Mesri M, Rodriguez H, Liebler DC (2013) Clinical Proteomic Tumor Analysis Consortium (CPTAC). Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov 3:1108–1112
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Scatena, R. (2015). Cancer Biomarkers: A Status Quo. In: Scatena, R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_1
Download citation
DOI: https://doi.org/10.1007/978-94-017-7215-0_1
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7214-3
Online ISBN: 978-94-017-7215-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)